Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285668 · ClinicalTrials.gov registry record · NA
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
A NA study of Hematologic Malignancies, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT07285668 is a NA study of Hematologic Malignancies that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 38 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07285668, a NA study of Hematologic Malignancies, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies.
Conditions Studied
Interventions
- DEVICE Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells
Study Locations (1)
Wisconsin
- UW Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2031-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07285668
The ClinicalTrials.gov registry entry for NCT07285668 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells is the first listed.
NCT07285668 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07285668 about?
NCT07285668 is a clinical study titled "Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies". This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies.
What is the current status of trial NCT07285668?
This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2026-02-26. Estimated completion is 2031-02.
What conditions does trial NCT07285668 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT07285668?
The interventions under investigation include: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells (DEVICE).
Who is sponsoring clinical trial NCT07285668?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07285668 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
RECRUITING · NA
-
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
COMPLETED · NA
-
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
COMPLETED · NA
-
IUdR/BUdR Cell Cycle Labelling
COMPLETED · NA
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.